What is povorcitinib studying in this clinical trial?

Povorcitinib is being studied to understand how it distributes in the skin and bloodstream after multiple doses in healthy adults. Researchers want to learn about the drug's movement and concentration in body fluids to support future medical use. The study is sponsored by Incyte Corporation and focuses on detailed drug behavior.

Who may be eligible for this healthy participant clinical trial?

Adults aged 18 to 65 who are healthy with a body mass index between 18.0 and 30.5 may be eligible. Participants must be able to swallow medication and avoid pregnancy during the study. People with certain health conditions, recent surgeries, or recent use of tobacco or investigational drugs may not qualify. Please review eligibility criteria for more details.

Is there any cost to participate in this clinical trial?

Study-related care, including the study drug or procedure and all trial visits, is provided at no cost. However, personal travel expenses and other costs may vary and are not guaranteed to be covered. Participants should plan accordingly for any related expenses.

Actively Recruiting

Phase 1

Age: 18Years - 65Years

All Genders

Healthy Volunteers

ID07588139

Study of Oral Povorcitinib and Topical Ruxolitinib Cream in Healthy Adults Using Skin Microperfusion and Blood Tests

Led by Incyte Corporation · Updated on 2026-06-03

Participants Needed

Research Sites

2 weeks

Total Duration

AI-Summary

What this Trial Is About

This research aims to study the levels of two drugs, povorcitinib taken by mouth and ruxolitinib cream applied to the skin, in the body fluids of healthy adults. The study focuses on measuring how these drugs distribute in the skin and blood after multiple doses. It is a phase 1 trial to better understand the pharmacokinetics, or how the drugs move and change within the body. Participants will receive either povorcitinib tablets at doses defined by the study or ruxolitinib cream applied twice daily to the skin. The study includes three groups, two receiving povorcitinib and one receiving ruxolitinib cream. The treatments are given over a period of up to 12 days, during which drug levels in skin fluid and blood will be collected and analyzed. During the study, participants will be closely monitored through various tests including blood draws and skin fluid sampling using an open-flow microperfusion device. Researchers will measure peak concentrations, area under the curve, and other pharmacokinetic parameters up to day 12. Safety will be assessed by tracking any adverse events until day 28. The total participation duration includes dosing and follow-up assessments to understand drug behavior and safety in healthy adults.

CONDITIONS

Brief Title

A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants

Who Can Participate

Age: 18Years - 65Years

All Genders

Healthy Volunteers

Eligibility Criteria

You may qualify if you...

Ability to understand and sign informed consent for the study.
Age between 18 and 65 years at the time of consent.
Body mass index between 18.0 and 30.5 kg/m2.
No clinically significant findings on screening tests including clinical, laboratory, and ECG evaluations.
Ability to swallow and keep oral medication.
Willingness to avoid pregnancy or fathering children during the study.

You will not qualify if you...

History of uncontrolled or unstable cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematopoietic, psychiatric, or neurological disease within 6 months before screening.
Any history of autoimmune disease.
History of cardiovascular, cerebrovascular, peripheral vascular, thrombotic disease, or uncontrolled high blood pressure.
Abnormal ECG history or presence.
Malabsorption syndromes affecting drug absorption (like Crohn's disease or chronic pancreatitis).
Any current or past malignancies except treated non-metastatic skin cancer or cervical carcinoma in situ.
Significant gastrointestinal disease or surgery within 3 months before screening (excluding appendectomy or hernia repair).
Major surgery within 4 weeks before screening.
Blood donation or participation in another clinical study within 4 weeks before screening (2 weeks for plasma-only donation).
Blood transfusion within 4 months before Day -1.
Active infectious diseases needing systemic treatment or known active tuberculosis.
Positive test for hepatitis B, hepatitis C, or HIV (exceptions for immunity status may apply).
Live vaccine within 3 months before first dose or anticipation to need during study (some vaccines excluded).
History of alcoholism or significant alcohol use within 3 months before screening.
Positive test for drugs of abuse or alcohol.
Treatment with other investigational drugs recently or enrollment in another investigational drug study.
Treatment with strong CYP3A4, P-gp, or BCRP inducers or inhibitors within 15 to 30 days before dosing.
Consumption of certain fruits or juices within 72 hours before first dose.
History of serious drug allergies relevant to study drugs.
Known severe reaction or allergy to study drugs or similar medications.
Inability to undergo blood sampling or tolerate venous access.
Tobacco or nicotine use within 1 month before screening.
Use of prescription or certain nonprescription drugs before dosing, with some exceptions.
Pregnant or breastfeeding women.
Conditions interfering with study participation or posing risk.
Excessive exercise within 7 days before Day -1.
Tattoos or scarring at skin sample sites.
Prone to keloid or hypertrophic scars or wound healing disorders.
Unwillingness to avoid certain activities or skin care before and after dosing.
Pronounced hairiness on application or sampling sites.
Needle phobia.
Increased risk of blood clots.
Other protocol-defined criteria may apply.

Research Team

Incyte Corporation Call Center (US)

Incyte Corporation Call Center (ex-US)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Study of Oral Povorcitinib and Topical Ruxolitinib Cream in Healthy Adults Using Skin Microperfusion and Blood Tests

On this page

AI-Summary

What this Trial Is About

Brief Title

Who Can Participate

Eligibility Criteria

Research Team

Not the Right Trial for You?

On this page

Who Can Participate

Eligibility Criteria